Skip to main content
Clinical Trials/NCT02526914
NCT02526914
Unknown
Not Applicable

Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making

David Mankuta1 site in 1 country432 target enrollmentOctober 2015

Overview

Phase
Not Applicable
Intervention
Intranasal Oxytocin
Conditions
Healthy
Sponsor
David Mankuta
Enrollment
432
Locations
1
Primary Endpoint
Preferences for competitive vs cooperative compensations and monetary allocations as measured by participants monetary allocations and compensation choice
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to investigate the role of a one-time intranasal administration of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and competition in a healthy population of student controls.

Registry
clinicaltrials.gov
Start Date
October 2015
End Date
October 2017
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
David Mankuta
Responsible Party
Sponsor Investigator
Principal Investigator

David Mankuta

David Mankuta, MD

Hadassah Medical Organization

Eligibility Criteria

Inclusion Criteria

  • healthy controls

Exclusion Criteria

  • Past or present psychiatric, neurological, endocrinological or severe chronic medical illness.
  • Use of medications or drugs that would interfere with study results. This includes steroids, medications for psychiatric symptoms like anxiety or depression, stimulants, and medications for high blood pressure. Participants will be asked to tell the investigators of any medications or drugs that they are taking. The investigators will consider the drug interactions with oxytocin and vasopressin prior to study, and participants will not be able to participate in the study if the drug interactions could be dangerous.
  • history of drug or alcohol addiction
  • Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women who are pregnant or nursing are excluded from this protocol. All females will have a pregnancy test performed no more than 24 hours before each drug administration and will not be able to participate if the pregnancy test is positive.

Arms & Interventions

Intranasal Oxytocin

Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).

Intervention: Intranasal Oxytocin

Intranasal vasopressin

Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).

Intervention: Intranasal vasopressin

Intranasal placebo

contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.

Intervention: Intranasal placebo

Outcomes

Primary Outcomes

Preferences for competitive vs cooperative compensations and monetary allocations as measured by participants monetary allocations and compensation choice

Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo

A group analysis will compare compensations preference (competitive vs. noncompetitive), performance and outcomes and monetary allocations on several economic games between the oxytocin, vasopressin and placebo groups.

Secondary Outcomes

  • Bargaining performance as assessed by participants' earnings in bargaining compensation(approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo)
  • Redistribution preferences as measured by participants' tax rate determination(approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo)
  • Willingness to compete as measured by participants compensation choice.(approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo)
  • Monetary offers in public goods game(approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo)
  • Monetary offers in all pay auction(approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo)
  • Negative hypothesis test strategy usage on Wason's-rule-discovery-task after exposure to trustworthy/untrustworthy face(approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo)
  • Positive and negative affect scale (PANAS)(approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo)
  • Fear of negative evaluation (FNE) as measured by self reporting(approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo)
  • Social value orientation as measured by monetary allocations preferences(approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo)

Study Sites (1)

Loading locations...

Similar Trials